BCDA - FDA Approves BioCardia's CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure

2023-11-14 07:47:47 ET

DENVER, Colo., Nov 14, 2023 ( www.247marketnews.com )- BioCardia Inc (NASDAQ: BCDA) stated, this morning, that the Food and Drug Administration (FDA) approved its Phase III clinical trial of its CardiAMP autologous cell therapy for the treatment of patients with ischemic heart failure and its proposed CardiAMP Heart Failure II study protocol.

BioCardia is trading at $0.7628, up $0.3638 (+91.18%), on 4.65M premarket shares.

Its 52-week range is $0.36 to $2.9199. It broe through a 2.5 month channel and is set to challenge several resistance points, if its strong trading volume continues.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to …

The post FDA Approves BioCardia’s CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure appeared first on 24/7 Market News .

For further details see: